ESPharma: what changed
ESPharma
Largest movements
- Receivables after one year +€40,000
new in 2025: €40,000
- Receivables within one year +€5,853
up €5,853 (+258%), from €2,269 to €8,122
- Cash +€1,470
up €1,470 (+5.9%), from €25,044 to €26,514
mainly Net result for the year (+€40,204) and Tax, wage and social debts (+€8,006)
- Profit (loss) carried forward +€39,371
up €39,371 (+269%), from €14,658 to €54,029
- Tax, wage and social debts +€8,006
up €8,006 (+85.8%), from €9,327 to €17,333
- Trade debts +€962
up €962 (+601%), from €160 to €1,122
- Other debts -€827
down €827 (-49.6%), from €1,669 to €841
- Gross operating margin +€30,617
up €30,617 (+149%), from €20,543 to €51,161
- Taxes +€7,150
up €7,150 (+178%), from €4,021 to €11,171
- Depreciation -€1,024
no longer reported in 2025 (was €1,024)
- Financial income +€700
new in 2025: €700
Change in the result, 2024 to 2025
For each income-statement line you see the change as its effect on the result. Higher costs lower the result, higher income raises it.
Derived cash bridge
The bridge is derived from the 2024 and 2025 balance sheets and the 2025 result. There is no filed cash-flow statement. You see where the money came from and where it went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €27,314 | €74,825 | +€47,511 | +174% |
| Current assets | 29/58 | €27,314 | €74,825 | +€47,511 | +174% |
| Amounts receivable after more than one year | 29 | - | €40,000 | +€40,000 | |
| Other amounts receivable | 291 | - | €40,000 | +€40,000 | |
| Amounts receivable within one year | 40/41 | €2,269 | €8,122 | +€5,853 | +258% |
| Trade receivables | 40 | €2,269 | €8,122 | +€5,853 | +258% |
| Cash at bank and in hand | 54/58 | €25,044 | €26,514 | +€1,470 | +5.9% |
| Deferred charges and accrued income | 490/1 | - | €189 | +€189 | |
| Total equity and liabilities | 10/49 | €27,314 | €74,825 | +€47,511 | +174% |
| Equity | 10/15 | €16,158 | €55,529 | +€39,371 | +244% |
| Contributions | 10/11 | €1,500 | €1,500 | = | 0.0% |
| Profit (loss) carried forward | 14 | €14,658 | €54,029 | +€39,371 | +269% |
| Amounts payable | 17/49 | €11,155 | €19,296 | +€8,140 | +73.0% |
| Amounts payable within one year | 42/48 | €11,155 | €19,296 | +€8,140 | +73.0% |
| Trade debts | 44 | €160 | €1,122 | +€962 | +601% |
| Suppliers | 440/4 | €160 | €1,122 | +€962 | +601% |
| Taxes, remuneration and social security | 45 | €9,327 | €17,333 | +€8,006 | +85.8% |
| Taxes | 450/3 | €9,327 | €17,333 | +€8,006 | +85.8% |
| Other amounts payable | 47/48 | €1,669 | €841 | -€827 | -49.6% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €1,024 | - | -€1,024 | |
| Other operating charges | 640/8 | - | €441 | +€441 | |
| Gross operating margin | 9900 | €20,543 | €51,161 | +€30,617 | +149% |
| Operating profit (loss) | 9901 | €19,520 | €50,719 | +€31,199 | +160% |
| Financial income | 75/76B | - | €700 | +€700 | |
| Recurring financial income | 75 | - | €700 | +€700 | |
| Financial charges | 65/66B | €8 | €45 | +€38 | +500% |
| Recurring financial charges | 65 | €8 | €45 | +€38 | +500% |
| Profit (loss) for the period before taxes | 9903 | €19,512 | €51,375 | +€31,862 | +163% |
| Income taxes | 67/77 | €4,021 | €11,171 | +€7,150 | +178% |
| Profit (loss) for the period | 9904 | €15,491 | €40,204 | +€24,713 | +160% |
| Profit (loss) for the period to be appropriated | 9905 | €15,491 | €40,204 | +€24,713 | +160% |
Next steps
Calculation and sources
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Green is a favourable move for that line, red an unfavourable one. Prepared on 3 November 2026 via checked.be.